Appropriateness of Specific Chemotherapy Regimens in Elderly Patients Diagnosed with Ovarian Cancer
Researchers studied the appropriateness of specific chemotherapy regimens in elderly patients diagnosed with ovarian cancer. In this randomized clinical trial, 120 vulnerable, older patients with ovarian cancer were randomized to receive 6 cycles of carboplatin at 5 mg/mL plus paclitaxel at 175 mg/m2 every 3 weeks, single-agent carboplatin at either 5 mg/mL or 6 mg/mL every 3 weeks or weekly carboplatin at 2 mg/mL plus paclitaxel at 60 mg/m2 on days 1, 8, and 15 every 4 weeks.
Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer.
The results indicated that single-agent carboplatin was less effective (i.e., associated with worse progression-free and overall survival outcomes) when compared with a conventional every-3-weeks carboplatin–paclitaxel regimen (6 cycles completed in 48% vs 60% of patients, respectively). Despite the toxicity associated with carboplatin and paclitaxel, the research findings suggest that a conventional doublet regimen is warranted for all adult patients diagnosed with ovarian cancer, irrespective of advanced age or health status.
About Women’s Cancer Research Foundation The Women’s Cancer Research Foundation (WCRF) is one of Southern California’s and the nation’s most active research organizations for female cancers. We are dedicated to serving the interests of patients, families, and friends affected by women’s cancers. WCRF partners with physician-scientists nationally to make differences in women’s lives by offering hope, strength, and progress.
361 Hospital Road, Suite 422
Newport Beach, CA 92663
PH: (949) 642-5165